Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products
- PMID: 6282507
- PMCID: PMC1536414
Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products
Abstract
The lipoxygenase products of arachidonic acid, 5-HPETE, 5-HETE, LTB4, LTC4 and LTD4, were examined for their capacity to enhance the expression of complement (C3b) receptors and to evoke chemotaxis of human neutrophils and eosinophils. With the exception of LTD4 all gave enhancement of C3b receptors. LTB4 and LTC4 enhanced over the concentration range 10(-7) to 10(-11) moles/l, and 5-HETE and 5-HPETE from 5 X 10(-6) to 5 X 10(-10) moles/l. The rank order of activity, as assessed by the magnitude of enhancement, was LTB4 (concentration for maximal effect = 10(-7) moles/l) greater than 5-HETE (5 X 10(-7)) greater than 5-HPETE (5 X 10(-6)) greater than LTC4 (10(-9)). High dose inhibition was observed with LTC4 and 5-HETE. Chemotaxis experiments performed in parallel over the same concentration ranges indicated that neither neutrophils nor eosinophils migrated towards LTC4 or LTD4. However, LTB4 evoked chemotaxis with a linear dose response from 10(-9) to 10(-7) moles/l and 5-HPETE and 5-HETE from 5 X 10(-8) to 5 X 10(-6) moles/l. At 10(-7) moles/l LTB4 was approximately 6 and 8 X more potent in chemotaxis than 5-HPETE and 5-HETE respectively. In general, complement receptor enhancement and chemotaxis of eosinophils were similar to that observed with neutrophils and did not vary with the patient source.
Similar articles
-
Mediation of leukocyte components of inflammatory reactions by lipoxygenase products of arachidonic acid.Adv Prostaglandin Thromboxane Leukot Res. 1982;9:273-82. Adv Prostaglandin Thromboxane Leukot Res. 1982. PMID: 6283846
-
Enhancement of neutrophil- and eosinophil-mediated complement-dependent killing of schistosomula of Schistosoma mansoni in vitro by leukotriene B4.Clin Exp Immunol. 1983 Jun;52(3):519-27. Clin Exp Immunol. 1983. PMID: 6307558 Free PMC article.
-
Metabolism of arachidonic acid through the 5-lipoxygenase pathway in normal human peritoneal macrophages.J Immunol. 1988 Sep 15;141(6):2104-9. J Immunol. 1988. PMID: 2844895
-
Lipoxygenase pathways of macrophages.Fed Proc. 1985 Nov;44(14):2933-6. Fed Proc. 1985. PMID: 2996948 Review.
-
The leukotrienes.Med Biol. 1984;62(4):215-30. Med Biol. 1984. PMID: 6096644 Review.
Cited by
-
A novel neutrophil-activating factor released by Trichomonas vaginalis.Infect Immun. 1992 Nov;60(11):4475-82. doi: 10.1128/iai.60.11.4475-4482.1992. Infect Immun. 1992. PMID: 1398962 Free PMC article.
-
Human polymorphonuclear leukocytes release leukotriene B4 during phagocytosis of Staphylococcus aureus.Inflammation. 1986 Mar;10(1):37-47. doi: 10.1007/BF00916039. Inflammation. 1986. PMID: 3007355
-
Pharmacological inhibition of leukotriene actions.Pharm World Sci. 1998 Apr;20(2):60-5. doi: 10.1023/a:1008698027211. Pharm World Sci. 1998. PMID: 9584338 Review.
-
Interferon-alpha enhances the production of leukotriene B4 in murine peritoneal macrophages stimulated by opsonized zymosan.Immunology. 1987 Apr;60(4):617-9. Immunology. 1987. PMID: 3034768 Free PMC article.
-
Macrophages cultured in vitro release leukotriene B4 and neutrophil attractant/activation protein (interleukin 8) sequentially in response to stimulation with lipopolysaccharide and zymosan.J Clin Invest. 1990 Nov;86(5):1556-64. doi: 10.1172/JCI114875. J Clin Invest. 1990. PMID: 2173722 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources